X4 Pharmaceuticals Reports Q3 Loss, Revenue Misses Estimate

X4 Pharmaceuticals reported a Q3 loss of $0.69 per share, missing revenue estimates by 7.2%. The company's shares have lost 82% since the beginning of the year, but the Zacks Rank #2 (Buy) suggests the stock is expected to outperform the market in the near future. The current consensus EPS estimate is -$0.44 on $2.1 million in revenues for the coming quarter and -$3.40 on $34.81 million in revenues for the current fiscal year.